ClinicalTrials.gg
CompletedNCT00436293Updated Nov 17, 2010

Taxotere + Cisplatin in Nasopharyngeal Carcinoma

A Phase 2 interventional study of Docetaxel and Cisplatin in Nasopharyngeal Neoplasms, sponsored by Sanofi. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-17.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies in Nasopharyngeal Neoplasms with a site in Hong Kong — none open to participants now, 1 under way, none of them phase 3. Nasopharyngeal Neoplasms · Hong Kong.

Enrollment
4th of 10
61 · median 44
Started
2002
the only one that year
Phase 2
6 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
2 of 10
Sanofi

Among the 10 studies in Nasopharyngeal Neoplasms with a site in Hong Kong, this one is the 4th largest by enrollment, is the only one that started in 2002, is one of 6 in phase 2, and was the 3rd registered.

Nasopharyngeal Neoplasms

226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.

Browse Nasopharyngeal Neoplasms studies →

Open to participants now

None of the 10 studies in Nasopharyngeal Neoplasms with a site in Hong Kong is open now. The open studies under Nasopharyngeal Neoplasms, anywhere →

Who these studies take

Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Nasopharyngeal Neoplasms with a site in Hong Kong as a file.
02

Study summary

Primary objective:

To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin.

Secondary objective:

To assess tumor control and survival

03

Conditions studied

  • Nasopharyngeal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • International Union against Cancer stages III and IV newly diagnosed NPC

Exclusion criteria

Exclusion Criteria:

  • Inadequate bone marrow reserve
  • Inadequate renal function
  • Other primary
  • Evidence of distant

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    1

    Neo-adjuvant Taxotere followed by cisplatin and radiotherapy

    Drug: Docetaxel

  • Active comparator
    2

    Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy

    Drug: Cisplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment response is evaluated by correlating findings on clinical examination, endoscopy, biopsy, Computed tomography or Magnetic resonance imaging as appropriate.

    Time frame: From administration of drug to end of study

Secondary outcomes

  1. Adverse Events

    Time frame: From administration of drug to end of study

07

Study locations

1 site
  • Sanofi-Aventis
    Hong Kong, Hong Kong
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2007
First posted
Feb 19, 2007
Start
Dec 2002
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Last update
Nov 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00436293
Lead sponsor
Sanofi
First posted
Feb 19, 2007
Start date
Dec 2002
Primary completion
Mar 2010
Completion
Mar 2010
Last update
Nov 17, 2010

Study contacts

Iris Chan
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion